Skip to main content
Erschienen in: Journal of Genetic Counseling 5/2018

22.02.2018 | Original Research

Psychosocial Impact of a Positive Gene Result for Asymptomatic Relatives at Risk of Hypertrophic Cardiomyopathy

verfasst von: Carissa Bonner, Catherine Spinks, Christopher Semsarian, Alex Barratt, Jodie Ingles, Kirsten McCaffery

Erschienen in: Journal of Genetic Counseling | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Families with a history of hypertrophic cardiomyopathy (HCM) may be offered genetic testing in addition to clinical surveillance. Asymptomatic family members who are gene positive (silent gene carriers) represent a new group of “patients” who may not develop HCM, with little evidence available to assist clinical management. This study explored experiences of HCM genetic testing to identify potential benefits and harms. Thirty-two individuals previously offered genetic testing for HCM were recruited. Semi-structured interviews were conducted face-to-face or by phone, and transcribed audio-recordings were coded using framework analysis. Key themes were as follows: (1) helping the next generation, (2) misunderstanding risk, (3) discrepancy between actual/perceived impact. Participants described multiple psychological (shock, worry, uncertainty) and behavioural (career, sport, insurance, family planning) consequences, depending on perceived risk. Most considered only the benefits of genetic testing for children or grandchildren, but there were some cases of significant adverse impact. The interpretation of the HCM genetic test result is variable for silent gene carriers and can lead to psychological and behavioural changes. The impact of a positive gene result may be mitigated by increased clarity of the clinical consequences and efforts to ensure informed decision-making, highlighting even further the important role of cardiac genetic counselling.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Aatre, R. D., & Day, S. M. (2011). Psychological issues in genetic testing for inherited cardiovascular diseases. Circulation. Cardiovascular Genetics, 4(1), 81–90.CrossRefPubMed Aatre, R. D., & Day, S. M. (2011). Psychological issues in genetic testing for inherited cardiovascular diseases. Circulation. Cardiovascular Genetics, 4(1), 81–90.CrossRefPubMed
Zurück zum Zitat Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., Camm, A. J., Ellinor, P. T., Gollob, M., Hamilton, R., Hershberger, R. E., Judge, D. P., Le Marec, H., McKenna, W. J., Schulze-Bahr, E., Semsarian, C., Towbin, J. A., Watkins, H., Wilde, A., Wolpert, C., & Zipes, D. P. (2011). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm, 8(8), 1308–1339.CrossRefPubMed Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., Camm, A. J., Ellinor, P. T., Gollob, M., Hamilton, R., Hershberger, R. E., Judge, D. P., Le Marec, H., McKenna, W. J., Schulze-Bahr, E., Semsarian, C., Towbin, J. A., Watkins, H., Wilde, A., Wolpert, C., & Zipes, D. P. (2011). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm, 8(8), 1308–1339.CrossRefPubMed
Zurück zum Zitat Alfares, A. A., Kelly, M. A., McDermott, G., Funke, B. H., Lebo, M. S., Baxter, S. B., Shen, J., McLaughlin, H. M., Clark, E. H., Babb, L. J., Cox, S. W., DePalma, S. R., Ho, C. Y., Seidman, J. G., Seidman, C. E., & Rehm, H. L. (2015). Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genetics in medicine : official journal of the Am College Med Genet, 17(11), 880–888.CrossRef Alfares, A. A., Kelly, M. A., McDermott, G., Funke, B. H., Lebo, M. S., Baxter, S. B., Shen, J., McLaughlin, H. M., Clark, E. H., Babb, L. J., Cox, S. W., DePalma, S. R., Ho, C. Y., Seidman, J. G., Seidman, C. E., & Rehm, H. L. (2015). Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genetics in medicine : official journal of the Am College Med Genet, 17(11), 880–888.CrossRef
Zurück zum Zitat Caleshu, C., Kasparian, NA, Edwards, KS, Yeates, L., Semsarian, C., Perez, M., Ashley, E., Turner, C. J., Knowles, J. W., Ingles, J.. (2016). Interdisciplinary psychosocial care for families with inherited cardiovascular diseases. Trends in Cardiovascular Medicine. Caleshu, C., Kasparian, NA, Edwards, KS, Yeates, L., Semsarian, C., Perez, M., Ashley, E., Turner, C. J., Knowles, J. W., Ingles, J.. (2016). Interdisciplinary psychosocial care for families with inherited cardiovascular diseases. Trends in Cardiovascular Medicine.
Zurück zum Zitat Christiaans, I., Birnie, E., Bonsel, G. J., Mannens, M. M., Michels, M., Majoor-Krakauer, D., Dooijes, D., van Tintelen, J. P., van den Berg, M. P., Volders, P. G., Arens, Y. H., van den Wijngaard, A., Atsma, D. E., Helderman-van den Enden, A. T., Houweling, A. C., de Boer, K., van der Smagt, J. J., Hauer, R. N., Marcelis, C. L., Timmermans, J., van Langen, I. M., & Wilde, A. A. (2011). Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. European Heart Journal, 32(9), 1161–1170.CrossRefPubMed Christiaans, I., Birnie, E., Bonsel, G. J., Mannens, M. M., Michels, M., Majoor-Krakauer, D., Dooijes, D., van Tintelen, J. P., van den Berg, M. P., Volders, P. G., Arens, Y. H., van den Wijngaard, A., Atsma, D. E., Helderman-van den Enden, A. T., Houweling, A. C., de Boer, K., van der Smagt, J. J., Hauer, R. N., Marcelis, C. L., Timmermans, J., van Langen, I. M., & Wilde, A. A. (2011). Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. European Heart Journal, 32(9), 1161–1170.CrossRefPubMed
Zurück zum Zitat Christiaans, I., van Langen, I. M., Birnie, E., Bonsel, G. J., Wilde, A. A., & Smets, E. M. (2009). Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients’ perspective. American Journal of Medical Genetics. Part A, 149A(7), 1444–1451.CrossRefPubMed Christiaans, I., van Langen, I. M., Birnie, E., Bonsel, G. J., Wilde, A. A., & Smets, E. M. (2009). Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients’ perspective. American Journal of Medical Genetics. Part A, 149A(7), 1444–1451.CrossRefPubMed
Zurück zum Zitat Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., Seidman, C. E., Towbin, J. A., Udelson, J. E., & Yancy, C. W. (2011). 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am College Cardiol, 58(25), e212–e260.CrossRef Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., Seidman, C. E., Towbin, J. A., Udelson, J. E., & Yancy, C. W. (2011). 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am College Cardiol, 58(25), e212–e260.CrossRef
Zurück zum Zitat Gray, B., Ingles, J., & Semsarian, C. (2011). Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 152(2), 258–259.CrossRefPubMed Gray, B., Ingles, J., & Semsarian, C. (2011). Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 152(2), 258–259.CrossRefPubMed
Zurück zum Zitat Hamang, A., Eide, G. E., Nordin, K., Rokne, B., Bjorvatn, C., & Oyen, N. (2010). Health status in patients at risk of inherited arrhythmias and sudden unexpected death compared to the general population. BMC Medical Genetics, 11, 27.CrossRefPubMedPubMedCentral Hamang, A., Eide, G. E., Nordin, K., Rokne, B., Bjorvatn, C., & Oyen, N. (2010). Health status in patients at risk of inherited arrhythmias and sudden unexpected death compared to the general population. BMC Medical Genetics, 11, 27.CrossRefPubMedPubMedCentral
Zurück zum Zitat Ho, C. Y., Lakdawala, N. K., Cirino, A. L., Lipshultz, S. E., Sparks, E., Abbasi, S. A., Kwong, R. Y., Antman, E. M., Semsarian, C., Gonzalez, A., Lopez, B., Diez, J., Orav, E. J., Colan, S. D., & Seidman, C. E. (2015). Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC. Heart Failure, 3(2), 180–188.CrossRefPubMed Ho, C. Y., Lakdawala, N. K., Cirino, A. L., Lipshultz, S. E., Sparks, E., Abbasi, S. A., Kwong, R. Y., Antman, E. M., Semsarian, C., Gonzalez, A., Lopez, B., Diez, J., Orav, E. J., Colan, S. D., & Seidman, C. E. (2015). Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC. Heart Failure, 3(2), 180–188.CrossRefPubMed
Zurück zum Zitat Ingles, J., Sarina, T., Kasparian, N., & Semsarian, C. (2013a). Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults with genetic heart disease. International Journal of Cardiology, 168(4), 3779–3784.CrossRefPubMed Ingles, J., Sarina, T., Kasparian, N., & Semsarian, C. (2013a). Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults with genetic heart disease. International Journal of Cardiology, 168(4), 3779–3784.CrossRefPubMed
Zurück zum Zitat Ingles, J., Yeates, L., Hunt, L., McGaughran, J., Scuffham, P. A., Atherton, J., & Semsarian, C. (2013b). Health status of cardiac genetic disease patients and their at-risk relatives. International Journal of Cardiology, 165(3), 448–453.CrossRefPubMed Ingles, J., Yeates, L., Hunt, L., McGaughran, J., Scuffham, P. A., Atherton, J., & Semsarian, C. (2013b). Health status of cardiac genetic disease patients and their at-risk relatives. International Journal of Cardiology, 165(3), 448–453.CrossRefPubMed
Zurück zum Zitat Ingles, J., Yeates, L., O’Brien, L., McGaughran, J., Scuffham, P. A., Atherton, J., & Semsarian, C. (2012). Genetic testing for inherited heart diseases: longitudinal impact on health-related quality of life. Genetics in Medicine, 14(8), 749–752.CrossRef Ingles, J., Yeates, L., O’Brien, L., McGaughran, J., Scuffham, P. A., Atherton, J., & Semsarian, C. (2012). Genetic testing for inherited heart diseases: longitudinal impact on health-related quality of life. Genetics in Medicine, 14(8), 749–752.CrossRef
Zurück zum Zitat Ingles, J., Zodgekar, P. R., Yeates, L., Macciocca, I., Semsarian, C., Fatkin, D., & CCGDCW Group. (2011). Guidelines for genetic testing of inherited cardiac disorders. Heart, Lung & Circulation, 20(11), 681–687.CrossRef Ingles, J., Zodgekar, P. R., Yeates, L., Macciocca, I., Semsarian, C., Fatkin, D., & CCGDCW Group. (2011). Guidelines for genetic testing of inherited cardiac disorders. Heart, Lung & Circulation, 20(11), 681–687.CrossRef
Zurück zum Zitat James, C. A., Tichnell, C., Murray, B., Daly, A., Sears, S. F., & Calkins, H. (2012). General and disease-specific psychosocial adjustment in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy with implantable cardioverter defibrillators: a large cohort study. Circulation. Cardiovascular Genetics, 5(1), 18–24.CrossRefPubMed James, C. A., Tichnell, C., Murray, B., Daly, A., Sears, S. F., & Calkins, H. (2012). General and disease-specific psychosocial adjustment in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy with implantable cardioverter defibrillators: a large cohort study. Circulation. Cardiovascular Genetics, 5(1), 18–24.CrossRefPubMed
Zurück zum Zitat Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E. (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation, 92(4), 785–789.CrossRef Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E. (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation, 92(4), 785–789.CrossRef
Zurück zum Zitat Maron, B. J., Yeates, L., & Semsarian, C. (2011). Clinical challenges of genotype positive (+)-phenotype negative (−) family members in hypertrophic cardiomyopathy. The American Journal of Cardiology, 107(4), 604–608.CrossRefPubMed Maron, B. J., Yeates, L., & Semsarian, C. (2011). Clinical challenges of genotype positive (+)-phenotype negative (−) family members in hypertrophic cardiomyopathy. The American Journal of Cardiology, 107(4), 604–608.CrossRefPubMed
Zurück zum Zitat Olivotto, I., & Ashley, E. A. (2015). INHERIT (inhibition of the renin angiotensin system in hypertrophic cardiomyopathy and the effect on hypertrophy—a randomised intervention trial with losartan). Glob Cardiol Sci Pract, 2015, 7.CrossRefPubMedPubMedCentral Olivotto, I., & Ashley, E. A. (2015). INHERIT (inhibition of the renin angiotensin system in hypertrophic cardiomyopathy and the effect on hypertrophy—a randomised intervention trial with losartan). Glob Cardiol Sci Pract, 2015, 7.CrossRefPubMedPubMedCentral
Zurück zum Zitat Ormondroyd, E., Oates, S., Parker, M., Blair, E., & Watkins, H. (2014). Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications. Eur J Human Genet, 22(1), 88–93.CrossRef Ormondroyd, E., Oates, S., Parker, M., Blair, E., & Watkins, H. (2014). Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications. Eur J Human Genet, 22(1), 88–93.CrossRef
Zurück zum Zitat Ritchie, J., Spencer, L., & O’Connor, W. (2003). Carrying out qualitative analysis. In J. Ritchie & L. Spencer (Eds.), Qualitative research practice: a guide for social science students and researchers (pp. 219–262). London: Sage. Ritchie, J., Spencer, L., & O’Connor, W. (2003). Carrying out qualitative analysis. In J. Ritchie & L. Spencer (Eds.), Qualitative research practice: a guide for social science students and researchers (pp. 219–262). London: Sage.
Zurück zum Zitat Semsarian, C., Ingles, J., Maron, M. S., & Maron, B. J. (2015). New perspectives on the prevalence of hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 65(12), 1249–1254.CrossRefPubMed Semsarian, C., Ingles, J., Maron, M. S., & Maron, B. J. (2015). New perspectives on the prevalence of hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 65(12), 1249–1254.CrossRefPubMed
Zurück zum Zitat Sweeting, J., Ingles, J., Ball, K., & Semsarian, C. (2015). Challenges of exercise recommendations and sports participation in genetic heart disease patients. Circulation. Cardiovascular Genetics, 8(1), 178–186.CrossRefPubMed Sweeting, J., Ingles, J., Ball, K., & Semsarian, C. (2015). Challenges of exercise recommendations and sports participation in genetic heart disease patients. Circulation. Cardiovascular Genetics, 8(1), 178–186.CrossRefPubMed
Zurück zum Zitat Van Driest, S. L., Ommen, S. R., Tajik, A. J., Gersh, B. J., & Ackerman, M. J. (2005). Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clinic Proceedings, 80(6), 739–744.CrossRefPubMed Van Driest, S. L., Ommen, S. R., Tajik, A. J., Gersh, B. J., & Ackerman, M. J. (2005). Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clinic Proceedings, 80(6), 739–744.CrossRefPubMed
Zurück zum Zitat Watkins, H., Ashrafian, H., & Redwood, C. (2011). Inherited cardiomyopathies. The New England Journal of Medicine, 364(17), 1643–1656.CrossRefPubMed Watkins, H., Ashrafian, H., & Redwood, C. (2011). Inherited cardiomyopathies. The New England Journal of Medicine, 364(17), 1643–1656.CrossRefPubMed
Metadaten
Titel
Psychosocial Impact of a Positive Gene Result for Asymptomatic Relatives at Risk of Hypertrophic Cardiomyopathy
verfasst von
Carissa Bonner
Catherine Spinks
Christopher Semsarian
Alex Barratt
Jodie Ingles
Kirsten McCaffery
Publikationsdatum
22.02.2018
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 5/2018
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-018-0218-8

Weitere Artikel der Ausgabe 5/2018

Journal of Genetic Counseling 5/2018 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.